---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-066144"
form_type: "8-K"
ticker: "AMGN"
cik: "0000318154"
company_name: "AMGEN INC"
filed_at: "2023-03-09T23:59:59+00:00"
generated_at: "2026-06-18T07:51:01.992278+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Amgen terminates $28.5B Horizon bridge facility, enters new $4B revolver

## Summary
- Bridge credit facility (originally $28.5B) for Horizon Therapeutics acquisition terminated March 9, 2023 after reductions from $4B term loan and $23.8B senior note proceeds.
- New $4.0B revolving credit agreement signed with 5-year initial term, extendable up to two additional years, for general corporate purposes and commercial paper backstop.
- Interest on revolver advances is Adjusted Term SOFR plus 0.68%-1.10% (or base rate plus 0.00%-0.10%) depending on Amgen's senior debt rating.
- Company states sufficient liquidity from term loan, note proceeds, and cash to complete Horizon acquisition; remaining bridge commitments were not needed.

## SEC filing metadata
- accession: 0001193125-23-066144
- form_type: 8-K
- ticker: AMGN
- cik: 0000318154
- company_name: AMGEN INC
- filed_at: 2023-03-09T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 1.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/318154/000119312523066144/0001193125-23-066144-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/318154/000119312523066144/d466407d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-066144
- JSON: https://secwatch.observer/filing/0001193125-23-066144.json
- Plain text: https://secwatch.observer/filing/0001193125-23-066144.txt

## Key facts
- Material Agreements
  AMGEN INC terminated Bridge Credit Facility with Citibank, N.A., Bank of America, N.A., and other lenders valued at $28.5 billion bridge credit facility terminated (effective 2023-03-09).
  - Action: termination
  - Agreement: credit facility
  - Counterparty: Citibank, N.A., Bank of America, N.A., and other lenders
  - Value: $28.5 billion bridge credit facility terminated
  - Effective: 2023-03-09
  source text: On March 9, 2023, we elected to terminate all remaining outstanding commitments under our Bridge Credit Facility and terminate the Bridge Credit Facility in its entirety in accordance with its terms.
  evidence_url: https://www.sec.gov/Archives/edgar/data/318154/000119312523066144/0001193125-23-066144-index.htm
- Material Agreements
  AMGEN INC entered into Third Amended and Restated Revolving Credit Agreement with Citibank, N.A., JPMorgan Chase Bank, N.A., and other banks valued at $4.0 billion revolving credit facility (effective 2023-03-09).
  - Action: entry
  - Agreement: credit facility
  - Counterparty: Citibank, N.A., JPMorgan Chase Bank, N.A., and other banks
  - Value: $4.0 billion revolving credit facility
  - Effective: 2023-03-09
  source text: On March 9, 2023, Amgen Inc. (the “Company”) entered into a third amended and restated revolving credit agreement with Citibank, N.A., as administrative agent (“Citibank”), JPMorgan Chase Bank, N.A., as syndication agent, and the other banks party thereto (the “Revolving Credit Agreement”), for a total commitment of $4.0 billion.
  evidence_url: https://www.sec.gov/Archives/edgar/data/318154/000119312523066144/0001193125-23-066144-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.